Company Valuation: BLS Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: June 2020 2021 2022 2023 2024 2025
Market Cap 1 6.401 17.92 7.682 38.03 10.23 88.76
Change - 180% -57.14% 395.11% -73.09% 767.35%
Enterprise Value (EV) 1 4.701 16.32 5.514 34.75 9.916 82.62
Change - 247.2% -66.22% 530.16% -71.46% 733.27%
P/E -10.8x -35x -30x -13.9x -0.72x 17.8x
PBR 2.5x 9.53x 4.07x 2.51x 2.84x 7.15x
PEG - 2.6x 0.6x -0x -0x -0x
Capitalization / Revenue 2.76x 8.13x 3.09x 7.17x 1.06x 3.03x
EV / Revenue 2.02x 7.4x 2.22x 6.55x 1.03x 2.82x
EV / EBITDA -15.6x -124x -38.9x -20.1x -9.16x 15.3x
EV / EBIT -14.4x -109x -36.2x -18.9x -8.75x 16.2x
EV / FCF 20.4x 34.5x 12.4x -63.8x -3.81x 29.2x
FCF Yield 4.9% 2.9% 8.05% -1.57% -26.3% 3.42%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -0.009265 -0.007999 -0.003999 -0.0144 -0.069 0.023
Distribution rate - - - - - -
Net sales 1 2.322 2.204 2.485 5.305 9.643 29.28
EBITDA 1 -0.3009 -0.132 -0.1416 -1.726 -1.082 5.402
EBIT 1 -0.3257 -0.1497 -0.1525 -1.836 -1.133 5.099
Net income 1 -0.5931 -0.4957 -0.2365 -1.94 -13.33 4.901
Net Debt 1 -1.7 -1.602 -2.168 -3.287 -0.3176 -6.134
Reference price 2 0.1000 0.2800 0.1200 0.2000 0.0500 0.4100
Nbr of stocks (in thousands) 64,015 64,015 64,015 190,165 204,665 216,483
Announcement Date 9/30/20 9/30/21 9/30/22 9/29/23 9/30/24 9/30/25
1AUD in Million2AUD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 150M
34.02x5.98x18.5x0.96% 49.92B
-23.69x348.44x-22.41x-.--% 40.23B
25.19x2.79x12.06x-.--% 34.55B
44.97x4.49x28.67x-.--% 33.09B
29.73x7.68x19.76x0.42% 27.51B
32.72x5.32x24.23x-.--% 15.92B
24.01x2.04x8.98x1.11% 13.86B
-22.69x14.88x-22.26x-.--% 13.52B
Average 18.03x 48.95x 8.44x 0.31% 25.42B
Weighted average by Cap. 19.55x 65.99x 9.36x 0.33%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. BXN Stock
  4. Valuation BLS Pharmaceuticals Limited